A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
Status:
Not yet recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
A study designed to assess the safety of MTX-110 alone and in combination with lomustine for
patients suffering with recurrent glioblastoma. MTX-110 will be administered directly to the
site of the tumour via a catheter which is inserted during a surgical procedure at the
beginning of the study.